P roteolysis targeting chimeras (PROTACs) are an emerging new class of drug molecules wherein a target-binding ligand linked covalently to an E3 ligase-binding ligand forms a target-PROTAC-ligase ternary complex, directing the ubiquitin proteasome system to degrade the target protein [1] [2] [3] . In contrast to classical small molecule drugs, PROTAC-driven degradation functions in a sub-stoichiometric nature, thus requiring lower systemic exposures to achieve efficacy 4, 5 . PROTACs have been shown to display higher degrees of selectivity for protein degradation than the target ligand itself due to complementarity differences in the proteinprotein interaction interfaces of the formed ternary complexes [6] [7] [8] [9] . In addition, PROTACs promise to expand the druggable proteome as degradation is not limited to the protein domain functionally responsible for the disease. In the case of challenging multidomain proteins, traditionally viewed as undruggable targets, the most ligandable domain can be targeted for degradation independent of its functionality or vulnerability to small molecule blockade 10, 11 . The ATP-dependent activities of the BAF (SWI/SNF) chromatin remodeling complexes affect the positioning of nucleosomes on DNA and thereby many cellular processes related to chromatin structure, including transcription, DNA repair and decatenation of chromosomes during mitosis 12, 13 . The BAF complex is mutated in approximately 20% of human cancers and contains one of two mutually exclusive ATPases, SMARCA2 or SMARCA4 [13] [14] [15] [16] . While SMARCA4 acts as a tumor suppressor in solid tumors, the role of SMARCA4 in acute myeloid leukemia (AML) is markedly different, such that it is required to maintain the oncogenic transcription program and drive proliferation 17 . Selective suppression of SMARCA2 activity has been proposed as a therapeutic concept for SMARCA4-mutated cancers [18] [19] [20] . A recent disclosure by Papillon et al. (published 5, 6, 10, 11, [25] [26] [27] . In the case of the BET protein BRD4, this has been achieved through the use of structure-based 
. In contrast to classical small molecule drugs, PROTAC-driven degradation functions in a sub-stoichiometric nature, thus requiring lower systemic exposures to achieve efficacy 4, 5 . PROTACs have been shown to display higher degrees of selectivity for protein degradation than the target ligand itself due to complementarity differences in the proteinprotein interaction interfaces of the formed ternary complexes [6] [7] [8] [9] . In addition, PROTACs promise to expand the druggable proteome as degradation is not limited to the protein domain functionally responsible for the disease. In the case of challenging multidomain proteins, traditionally viewed as undruggable targets, the most ligandable domain can be targeted for degradation independent of its functionality or vulnerability to small molecule blockade 10, 11 . The ATP-dependent activities of the BAF (SWI/SNF) chromatin remodeling complexes affect the positioning of nucleosomes on DNA and thereby many cellular processes related to chromatin structure, including transcription, DNA repair and decatenation of chromosomes during mitosis 12, 13 . The BAF complex is mutated in approximately 20% of human cancers and contains one of two mutually exclusive ATPases, SMARCA2 or SMARCA4 [13] [14] [15] [16] . While SMARCA4 acts as a tumor suppressor in solid tumors, the role of SMARCA4 in acute myeloid leukemia (AML) is markedly different, such that it is required to maintain the oncogenic transcription program and drive proliferation 17 . Selective suppression of SMARCA2 activity has been proposed as a therapeutic concept for SMARCA4-mutated cancers [18] [19] [20] . A recent disclosure by Papillon et 18, 22, 23 . Although cells lacking SMARCA4 activity are vulnerable to the loss of SMARCA2 18 , SMARCA2/4 BD inhibitors have failed to phenocopy these anti-proliferative effects. Indeed, reexpression of SMARCA2 variants in cells, where the endogenous protein had been suppressed, showed that an intact bromodomain is not required to maintain proliferation 24 . SMARCA2/4 BD inhibitors are thus precluded from use for the treatment of SMARCA4 mutant cancers but could provide attractive ligands for PROTAC conjugation. Small molecules binding to other bromodomains have been successfully converted into PROTACs by conjugating them with structures capable of binding to the E3 ligases von Hippel− Lindau (VHL) or cereblon 5, 6, 10, 11, [25] [26] [27] . In the case of the BET protein BRD4, this has been achieved through the use of structure-based . We therefore reasoned that a PROTAC targeting the non-functional bromodomain of SMARCA2/4 should offer an opportunity to exploit the vulnerability of SMARCA2-or SMARCA4-dependent cancer cells for therapeutic purposes.
Here, we show how structure-based PROTAC design enabled the identification of a potent degrader of SMARCA2 and SMARCA4 with anticancer activity. Biophysical analysis identified a prototype that forms cooperative ternary complexes, electing it as a lead for further investigation. Co-crystallization of ternary complexes guided rational design to yield an optimized chemical probe, ACBI1, in only two design steps. With this compound we demonstrate how depletion of the ATPases can lead to a reduction in other BAF/PBAF subunits within these stable complexes due to dissociation following SMARCA2/4 depletion. Furthermore, rapid and profound PROTAC-induced knockdown of SMARCA2/4 led to pronounced anti-proliferative effects and apoptosis across multiple cancer cell lines, substantiating the potential of targeted degradation of BAF complex ATPases as a viable cancer therapeutic strategy.
Results
Identification of a partial SMARCA2/4 degrader. To identify a targeted SMARCA degrader we first looked to select a suitable binding ligand. Great effort has been applied to discover SMARCA bromodomain inhibitors, so we turned our attention to a series of 2-(6-aminopyridazin-3-yl)phenols reported to possess robust SMARCA2/4 binding 22, 28, 29 . To elucidate the binding mode of these ligands and guide PROTAC conjugation design, we solved the cocrystal structure of a piperazine substituted SMARCA BD ligand (1) with SMARCA2 BD (Fig. 1a and Supplementary Table 1 , Protein Data Bank (PDB) ID 6HAZ). The observed binding mode is characterized by an interaction deep in the acetyl-lysine binding site between the phenol of the ligand and Y1421 as well as a donor/acceptor interaction between the aminopyridazine core and N1464. The piperazine ring of the ligand protrudes out into the solvent, suggestive of a suitable vector for PROTAC linkage. To recruit the von Hippel−Lindau (VHL) E3 ubiquitin ligase, we chose a VHL ligand with high affinity and known binding mode, recently published by our group 30 . Previous data also suggested a phenolic linkage point would be tolerated by VHL and simultaneously permit incorporation of the affinity-improving fluorocyclopropyl amide group [30] [31] [32] . By combining these observations and using polyethylene glycolbased linkers, a small set of PROTACs were designed and subsequently evaluated. Effective PROTACs have been shown to induce stabilizing protein-protein interactions of the E3 ligase with the target protein, leading to cooperative formation of a ternary complex in which the affinity of the PROTAC to both its binding partners is higher than when binding to each protein individually 7, 32, 33 . In isothermal titration calorimetry (ITC) assays, binding of PROTAC 1 (2) with the VHL-ElonginC-ElonginB (VCB) complex displays 4.8-fold greater affinity when already in complex with SMARCA2 BD than it does alone, indicating that ternary complexes formed by this . The piperazine ring was selected as an exit vector for PROTAC linkage as it is directed into solvent away from the binding site. b, Two-dimensional chemical structure of PROTAC 1. c, Inverse ITC titrations of VCB into PROTAC 1 (left) and VCB into the preformed PROTAC 1-SMARCA2 BD complex (right), n = 2. PROTAC 1 binds VCB with higher affinity when in complex with SMARCA2
BD and is therefore cooperative, α = 4.8. d, Degradation of SMARCA2 and SMARCA4 in MV-4-11 cells following treatment with PROTAC 1, analyzed via capillary electrophoresis (see Methods). For SMARCA2 and SMARCA4, maximal degradation is ~65 and ~70%, and concentration of compound required for half-maximal degradation (DC 50 ) is 300 and 250 nM, respectively. Data represent two biologically independent experiments. PROTAC are positively cooperative (Fig. 1b,c and Supplementary  Fig. 1a,b) . We also observed that PROTAC 1 was able to induce partial degradation of SMARCA2 and SMARCA4 in MV-4-11 cells (Fig. 1d) . PROTAC 1 showed a greater than ten-fold weaker binding affinity for the SMARCA bromodomain when compared to the SMARCA BD ligand, as measured by surface plasmon resonance (SPR) (Supplementary Table 2 ). This drop-off in binary affinity, perhaps due to an inhibitory conformation of the PROTAC for binding to the ATPase bromodomain, would be classically viewed as a step in the wrong direction. However, the cooperative nature, and so the enhanced binding affinity of PROTAC 1 when forming the key ternary complex species, encouraged us to investigate this compound further.
To rationalize the cooperative recognition and potentially enable structure-based PROTAC design we solved a high-resolution co-crystal structure of the ternary complex of VCB:PROTAC 1:SMARCA2 BD (2.25 Å, PDB ID 6HAY, Fig. 2a ,b, Supplementary Table 1 and Supplementary Figs. 1c and 2 ). The crystal structure contains two copies of the ternary complex in the asymmetric unit, with minor differences between them. The binding mode of PROTAC 1 with both SMARCA2 BD and VHL in the ternary complex recapitulates the key elements of the respective binary structures for each isolated binder, with a minor rearrangement of the BC loop of SMARCA2
BD when compared to the co-crystal structure of the SMARCA BD ligand, to accommodate close packing against VHL ( Supplementary Fig. 1c ). Of particular note, de novo protein-protein interactions were observed in the region of the BC loop of SMARCA2 BD and the periphery of the VHL-binding site (Fig. 2a) . The interface appears to be stabilized by an electrostatic interaction between R69 of VHL and the carbonyl groups of residues T1462 and F1463 that form the electronegative C-cap of the B helix of SMARCA2 BD , as well as a hydrogen bond between Y112 of VHL and N1464 of SMARCA2 BD (Fig. 2c) . Close packing of these residues around the fluorocyclopropyl amide group is a key feature of this ternary complex crystal structure. Collapse of the flexible polyethylene glycol-based linker onto a lipophilic face created in part by Y98 of the VHL protein is also visible in the structure (Fig.  2d) . In a Caco-2 permeability assay, we observed a very low A-B rate of 1.1 × 10 −7 cm s −1
, a B-A rate of 20.7 × 10 −6 cm s −1 and, therefore, an efflux permeability ratio of 190 for PROTAC 1, indicating poor passive permeability (A-B) and a high degree of transportermediated efflux (see Methods). Taken together, our data suggest that PROTAC 1 forms moderately cooperative ternary complexes allowing for subsequent degradation and is probably limited by cellular permeability.
Structure-based design of a SMARCA2/4 degrading PROTAC. To avoid lengthy empirical exploration of structure-activity relationships based on PROTAC 1, we endeavored to use the ternary complex co-crystal structure to efficiently guide us toward the design of a more optimal degrader. Inspection of the ternary complex structure of PROTAC 1 indicates that a large proportion of the de novo protein-protein interactions exist around the fluorocyclopropyl amide moiety (Fig. 2a,c) . Further, this crystal structure also points toward all other hydrogen bond donor containing functionalities in PROTAC 1 being engaged in PROTAC-protein interactions. We therefore decided to leave these regions unchanged and optimized the linker interaction with the lipophilic face. To increase conformational restraint, and attempt to form pi-stacking interactions to Y98, we introduced a benzylic group attached to the piperazine of the SMARCA-binding motif. Aware that linker geometry could play an important role in defining the ternary complex arrangement, we used a 1,4-substitution of the newly introduced phenyl ring to mimic the linker conformation observed for PROTAC 1 in our ternary complex structure and substantially reduce the polarity of the linker. The resulting compound, PROTAC 2 (3), exhibited a more favorable molecular recognition for the SMARCA BD within the ternary complex ( Fig. 3a and Table 3 ). This structure reveals a near identical ternary complex to that observed with PROTAC 1 with all de novo protein-protein and protein-PROTAC interactions maintained. As designed, the 1,4-substitution of the newly introduced phenyl ring in PROTAC 2 indeed recapitulates the geometry of the more flexible linker of PROTAC 1 (Fig. 3c) , . ACBI1 forms more cooperative and stable complexes compared to PROTAC 1. Curves are a best fit of means from n = 3 biologically independent experiments, ±s.e.m. f, Fitted curves for TR-FRET assays measuring displacement of a biotinylated SMARCA2 BD probe by PROTAC alone, in complex with VCB or in complex with an R69A variant of VCB. A significant rightward shift when using VCB R69A versus VCB highlights the importance of this residue in ternary complex formation in solution. Curves are a best fit of means from n = 3 biologically independent experiments, ±s.d.
with the phenyl ring forming an ideal T-stack to Y98 of VHL. In addition, the co-crystal structure for VCB:PROTAC 2:SMARCA4 BD was solved (1.76 Å resolution, PDB ID: 6HR2, Supplementary Fig. 3 and Supplementary Table 3) showing negligible differences in complexes formed by the bromodomains of either of the two ATPases with PROTAC 2 and VCB.
A series of competition biophysical assays were also established to further understand the formation of ternary complexes induced by PROTAC 1 and PROTAC 2. When using PROTAC 1, all assays produced data in good agreement with the ITC data obtained earlier for formation of VCB:PROTAC 1:SMARCA2 BD complexes (Supplementary Tables 2 and 4) . A fluorescence polarization assay was developed to measure displacement of a VHL-binding HIF-1α peptide and to determine the stability and cooperativity of ternary complexes (Supplementary Table 2 and Supplementary Fig. 4 ) 30, 34 . The data show that cooperativity (α) and ternary K i values for VCB:PROTAC:BAF unit complexes are significantly improved for PROTAC 2 as compared to PROTAC 1. Furthermore, the free energy change of the two-step complex formation process (ΔG complex ), calculated as a sum of ΔG values derived from the binary interaction of PROTAC with SMARCA2 BD (from SPR K d ) and ternary complex formation of SMARCA2 BD :PROTAC complex with VCB (from fluorescence polarization, K i ) was found to be 1.4 kcal mol -1 lower for PROTAC 2 compared with PROTAC 1 (Supplementary Table 5 ). This shift is equivalent to a ten-fold increase in ternary complex stability as a result of the structure-based optimization. Time resolved fluorescence energy transfer (TR-FRET) -based competition assays, measuring the displacement of a biotinylated SMARCA2 probe (4) in the presence or absence of VCB, were developed as an orthogonal approach to the fluorescence polarization assay. In TR-FRET competition assays, cooperativity of PROTAC 2 is likewise improved relative to PROTAC 1 (Supplementary Table 4 and Supplementary  Fig. 5 ). Using the same biotinylated SMARCA2 probe, the cooperative nature of both compounds was confirmed in an AlphaLISA assay evaluating PROTAC-induced ternary complexes between full-length proteins within cell lysates (Supplementary Table 6 and Supplementary Fig. 6 , see Methods for details).
Emboldened by our crystallographic and biophysical data, we sought to further optimize our degrader by maintaining the benzylic functionality on the piperazine that had produced improvements in PROTAC 2, while extending to the same linker length that had been employed in PROTAC 1, by introducing an oxygen atom between the VHL ligand and the phenyl ring of the linker (Fig. 3a) . On the basis of this design rationale, ACBI1 (5) was prepared and also subjected to evaluation in our fluorescence polarization and TR-FRET biophysical assays ( , a B-A rate of 3.8 × 10 −6 cm s −1 and an efflux ratio of 1.7.
The ternary complex crystal structures for PROTAC 1 and PROTAC 2 both suggest a key stabilizing role of the electrostatic interaction between R69 of VHL and the electronegative C-terminal cap of the B helix of SMARCA2 BD . To validate the specificity of the induced PPI in solution a modified VCB complex with an R69A mutation in VHL (VCB R69A ) was used. As predicted by the ternary crystallographic data, a significant decrease in cooperativity is seen for all PROTACs when VCB R69A is used in the TR-FRET assay relative to wild-type (Fig. 3f , Supplementary Table 4 and Supplementary  Fig. 5 ). Notably, irrespective of the initial cooperativity when using VCB, for all PROTACS the cooperativity values revert to ~3-4 when using VCB R69A , indicating a limit to the level of molecular recognition possible when this arginine residue is not present as an anchor point for these complexes. This data is also highly suggestive that an interaction between R69 of VHL and SMARCA2 BD is similarly important for molecular recognition within the ternary complex formed by ACBI1, as it is for PROTAC 1 and PROTAC 2.
Next, we evaluated the activity of our PROTACs in cellular assays (Fig. 4a,b and Supplementary Figs. 10 and 11). Complete and potent degradation induced by ACBI1 was observed for SMARCA2 (DC 50 of 6 nM) and SMARCA4 (DC 50 of 11 nM) in MV-4-11 cells, with similar effects on SMARCA2 in SMARCA4-deficient NCI-H1568 cells. The SMARCA BD ligand used in our PROTACs also binds to the fifth bromodomain of the PBAF complex member PBRM1, and ACBI1 is also seen to degrade that protein with a DC 50 of 32 nM. As expected, degradation by PROTAC 2 was sensitive to competition with a VHL inhibitor (6) and was dependent on neddylation 35 and proteasome activity ( Supplementary Fig. 11 ). Using 1 µM ACBI1, half maximal degradation occurred well within 2 h for SMARCA2 and SMARCA4 in MV-4-11 cells (Fig. 4a ). In line with increased ternary complex stabilities and expected permeabilities based on evaluation in Caco-2 assays, ACBI1 is a more potent degrader than PROTAC 2, which in turn is more potent than PROTAC 1.
To understand the wider effects of our PROTACs on the cellular proteome, unbiased quantitative tandem mass tag (TMT) labeling and mass spectrometry proteomics was performed with 333 nM of ACBI1 or cis-ACBI1 (7) and a treatment time of 8 h in MV-4-11 cells (Fig. 4c) . The data corroborate a significant knockdown of SMARCA2, SMARCA4 and PBRM1 with minimal down-regulation of other proteins across the proteome. To further understand the effects of chemically induced ATPase degradation on BAF/PBAF complex integrity, we immunoprecipitated complexes from cell extracts using antibodies against the SMARCC2/BAF170 and ARID1A subunits and identified specifically enriched associating proteins by mass spectrometry. Treatment with PROTAC 2 led, as expected, to a less efficient recovery of SMARCA2, SMARCA4 and PBRM1 ( Fig. 4d and Supplementary Figs. 12 and 13). The majority of accessory subunits remain associated, but it is clear that some core subunits, such as ACTL6A, the BAF specific BCL proteins and the PBAF specific PHF10 protein, are co-depleted. The TMT proteomics data with both PROTAC 2 and ACBI1 show no reduction in ACTL6A suggesting dissociation of this subunit from the complex following ATPase degradation ( Fig. 4c and Supplementary Fig. 12a ).
Degradation of SMARCA2/4 causes cancer cell death. The ATPases of the BAF complex have been shown to be essential in certain cancer cell lines. SMARCA4 supports AML cell proliferation by maintaining an essential enhancer 17 , whereas in several solid cancer types, mutational loss of SMARCA4 leads to a dependence on active SMARCA2 [18] [19] [20] 24 . We therefore tested the effects of PROTACmediated loss of SMARCA2 and SMARCA4 on proliferation of a panel of cancer cell lines ( Fig. 5a and Supplementary Fig. 14) . We first tested the activity of ACBI1 on cells known to depend on an intact BAF complex: leukemia cell lines, such as MV-4-11, as well as the SMARCA4-deficient cells SK-MEL-5 and NCI-H1568. In all cell lines tested, ACBI1 exerted potent anti-proliferative effects. In MV-4-11 and SK-MEL-5 cells, its non-degrading distomer cis-ACBI1 remained inactive. ACBI1 demonstrated an anti-proliferative IC 50 of 28 nM in MV-4-11 cells, broadly in line with its DC 50 of 6 nM. The SMARCA BD ligand, that is the bromodomain binder without the linker and VHL-binding part, had no anti-proliferative effect in any cell line. An anti-proliferative effect was seen with cis-ACBI1 in NCI-H1568 cells, albeit at a substantially higher concentration than ACBI1 (IC 50 of 441 nM versus 68 nM, Supplementary  Fig. 14b ). The reasons for this effect are presently unclear. A series of studies were next carried out to demonstrate that the effects of the PROTACs were due to on-target degradation of SMARCA2 and SMARCA4. First, we combined high amounts of the SMARCA BD ligand with titrations of ACBI1 to compete for bromodomain binding. As expected, competing amounts of SMARCA BD ligand reduced ACBI1-induced degradation of SMARCA2 as well as the negative effects on cell proliferation ( Fig. 5b and Supplementary Fig. 14c,d ). Second, a lung adenocarcinoma cell line deficient in both SMARCA2 and SMARCA4, NCI-H1703, was chosen to assess potential offtarget activity of ACBI1. Both ACBI1 and cis-ACBI1 show no antiproliferative effects in this SMARCA2/4 null cell line (Fig. 5a ). These cells remain competent to degrade BAF complex members, as ectopically expressed SMARCA2 was efficiently eliminated in the presence of PROTAC 2, but not the non-VHL-binding compound, cis-PROTAC 2 (8) (Supplementary Fig. 15a ). SMARCA2 bearing an inactivating mutation (see Methods) in the bromodomain (SMARCA2 bromodead) was stable in the presence of PROTAC 2, confirming that degradation depends on the compound interacting with an intact SMARCA2 bromodomain ( Supplementary Fig. 15a ). In NCI-H1568 cells overexpressing PBRM1, ACBI1 showed a similar anti-proliferative effect in comparison to a vector control, whereas the overexpression of SMARCA2 produced a significant rightward shift in anti-proliferative IC 50 as well as attenuating the maximal effect ( Supplementary Fig. 15b-d) . Taking into consideration that ACBI does not induce degradation of proteins other than SMARCA2, SMARCA4 and PBRM1, this supports insufficient amounts of SMARCA2 following ACBI1 treatment being the driver of the observed phenotype.
We then assessed the extent of cellular apoptosis induced by compound treatment. ACBI1-mediated loss of SMARCA2 led to increased caspase activity in SK-MEL-5, comparable to that seen with the chemotherapeutic drug doxorubicin (Fig. 5c) . In SK-MEL-5 Two independent experiments. b, Degradation of endogenous SMARCA2 in NCI-H1568 cells treated for 18 h gave a DC 50 of 3.3 nM for SMARCA2 and 15.6 nM for PBRM1. Two independent experiments. c, Effects of ACBI1 (blue) and cis-ACBI1 (red) at 333 nM for 8 h on the proteome of MV-4-11 cells. Data plotted log 2 of the fold change versus DMSO control against -log 10 of the P value per protein from n = 3 independent experiments. All t-tests performed were two-tailed t-tests assuming equal variances. d, SWI/SNF complexes were immunopurified from MV-4-11 cell lysates following PROTAC treatment and abundance of subunits was determined by label free quantitation. Data plotted as fold change in abundance for PROTAC 2 versus cis-PROTAC 2 treatment against -log 10 of the P value per protein from n = 3 biologically independent experiments. Subunits of the SWI/ SNF complex are highlighted. All t-tests performed were two-tailed assuming equal variances.
cells, the fraction of caspase-positive cells steeply increased after 40 h of treatment alongside the appearance of cleaved PARP, confirming the induction of apoptosis in these cells ( Supplementary  Fig. 15e ). These results confirm that the vulnerability of cancer cells to SMARCA subunit loss demonstrated by genetic means can be recapitulated by chemically induced degradation.
Discussion
In this study, we describe how structure-based design guided us to improve the characteristics of a bifunctional degrader molecule. We showed that despite binding to the protein target of interest with weaker affinity than the analogous SMARCA BD ligand, a prototype compound PROTAC 1 formed cooperative ternary complexes and was active as a degrader, and thus a promising lead for PROTAC optimization. Co-crystal structures identified the key induced interactions that were central to stabilize the ternary complex and delineated the conformation and interactions of the polyethylene glycol linker. This information saved considerable time and effort by guiding us away from changing regions of the PROTAC structure that could have been inhibitory to complex formation, a likely path if following an empirical approach. Rather, this data informed the introduction of a disubstituted phenyl ring to enhance conformational restraint and form new protein-linker interactions, while simultaneously reducing polarity of the molecule in a targeted way to give PROTAC 2. A subsequent ternary co-crystal structure and allied biophysical studies with PROTAC 2 showed improvements in molecular recognition and free energy of ternary complex formation for this compound, validating the design hypotheses. In a further round of design, the linker length was extended to that used in PROTAC 1 while retaining the benzyl moiety on the piperazine ring to yield ACBI1. These three PROTACs showed progressively more cooperative behavior in fluorescence polarization and TR-FRET ternary complex assays. In line with this and with improvements in permeability, these PROTACs induced degradation of their targets with increasing potency in cells. Our findings together qualify ACBI1 as a potent degrader of BAF complex ATPases in multiple cancer cell lines, and furnish a chemical tool for acute and profound SMARCA2/4 knockdown.
We exemplify the efficiency of structure-based PROTAC design and further demonstrate how non-functional domains can provide suitable handles for targeted degradation 10 . Prioritizing and designing bifunctional molecules on the basis of their ability to induce stable complexes between the E3 ligase and the target is broadly applicable and may greatly reduce the empirical nature of PROTAC design that has dominated until now. While cooperativity of ternary complexes is not essential for PROTAC-induced protein degradation 8, 33, 36 , we show that the identification of compounds that induce stable complexes can provide rational starting points for optimization, even if those molecules are suboptimal at inducing protein degradation or retaining the binary binding affinity of the constitutive target/ligase-binding units.
Unbiased whole cell proteomic analysis confirmed exquisitely selective ACBI1-mediated target protein knockdown and immunoprecipitation-mass spectrometry (IP-MS) experiments with its PROTAC 2, showed that the majority of BAF/PBAF subunits remain associated following PROTAC treatment. Several BAF subunits including ACTB, ACTL6A, BCL7A and PHF10 were consistently co-depleted from immunopurified complexes with SMARCA2, SMARCA4 and PBRM1. Many of these proteins are known to interact with SMARCA2, SMARCA4 and PBRM1 and are likely to dissociate as a result of loss of contact with these subunits, supported by our data showing total protein levels of ACTL6A are not changed 20, 37, 38 . At the outset of our study, it was not known if degradation of individual subunits out of stable BAF/PBAF multiprotein complexes by PROTACs was possible. By addressing this we have demonstrated the potential for acute chemically mediated manipulation of BAF/PBAF composition, which is of value both in the design of future therapeutics and as research tools.
The dependence of certain cancer types on the BAF complex paralog ATPases SMARCA2 and SMARCA4 has been unequivocally shown both by RNA interference and CRISPR-based knockouts [18] [19] [20] 24, 39, 40 . However, chemically induced knockdown targeting these BAF complex subunits has not been demonstrated so far. Our work shows that targeting the SMARCA2/4 bromodomains for protein degradation can exploit these identified cancer vulnerabilities and phenocopies the genetic knockdowns. The nature of the anti-proliferative effect of loss of BAF complex members has not been comprehensively investigated 20 . We show here that SMARCA2/4-degrading PROTACs can induce rapid apoptosis in a subset of SMARCA4-deficient cells. Additional studies are required to understand the differential rate in responses of a subset of cancer cells that have adapted to loss of SMARCA4 (for example, NCI-H1568 versus SK-MEL-5). Using our dual SMARCA2/4-degrading PROTACs, we were also able to show anti-proliferative effects in AML cells, consistent with earlier knockdown studies showing sensitivity of these cells to SMARCA4 depletion 17 . While mice lacking functional SMARCA2 develop normally, the loss of SMARCA4 results in embryonic death in mice [39] [40] [41] [42] . Therefore, while it is likely that a selective degrader of SMARCA2 will not have dramatic ontarget side effects, it remains to be seen whether SMARCA4 degradation can be therapeutically translated. In addition to targeting the BAF complex ATPases, ACBI1 also causes degradation of PBRM1, albeit with lower potency. However, overexpression of PBRM1 in NCI-H1568 cells failed to rescue the effects of ACBI1 on cell growth whereas SMARCA2 overexpression indeed attenuated the effect, suggesting that that loss of PBRM1 alone does not exert the antiproliferative effects observed. Future studies are warranted toward deeper mechanistic understanding of the downstream effects of degrading BAF ATPase subunits in both cancerous and non-cancerous cells. We anticipate that progress in this direction will be greatly advanced by sharing the chemical tools that have emerged from our work with the wider community. Finally, we hope that structurebased design becomes a central approach in the emerging PROTAC field as it has in more traditional areas of drug discovery.
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Methods
Chemical synthesis. Synthesis of compounds described in this paper and their intermediates are described in the Supplementary Note.
Cell lines and culture. Cell lines were obtained through ATCC, verified for identity by satellite repeat analysis and tested for mycoplasma contamination. Cells were grown in the medium as specified by the supplier unless described otherwise and not used beyond passage 25. 2) containing 0.25% BSA to prepare the transport solutions (0.1-300 µM compound, final dimethyl sulfoxide (DMSO) concentration ≤0.5%). Transport solution (TL) was applied to the apical or basolateral donor side for measuring A-B or B-A permeability (three filter replicates), respectively. The receiver side contained HTP-4 buffer supplemented with 0.25% BSA. Samples were collected at the start and end of experiment from the donor and at various time intervals for up to 2 h also from the receiver side for concentration measurement by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Sampled receiver volumes were replaced with fresh receiver solution.
Caco
Constructs, protein expression and purification of VCB and SMARCA2, SMARCA4 and PBRM1 bromodomains. Wild-type and mutant versions of human proteins were used for all protein expression, as follows: VHL (UniProt accession number P40337), ElonginC (Q15369), ElonginB (Q15370) and the bromodomains (BDs) of SMARCA2 (SMARCA2 BD ; P51531-2, residues 1373-1493 with additional N-terminal SM residues (cloning artifact)), SMARCA4 (SMARCA4 BD ; P51532, residues 1448-1569 with additional N-terminal SM residues (cloning artifact)) and the fifth bromodomain of PBRM1 (PBRM1 BD5 , Q86U86, residues 645-766). SMARCA4 BD was provided by the Structural Genomics Consortium (SGC), Toronto 43 and SMARCA2 BD and PRM1 BD5 were synthesized by GeneArt then subcloned into pDEST15 vectors (Invitrogen). The VCB complex was expressed and purified as described previously, with the modification that 0.3 mM IPTG was used for induction of expression 7 . Briefly, N-terminally His 6 -tagged VHL (54-213), ElonginC (17-112) and ElonginB (1-104) were co-expressed and the complex isolated by Ni-affinity chromatography, the His 6 tag was removed using TEV protease, and the complex further purified by anion exchange and size-exclusion chromatography (SEC). The VCB R69A mutant, in which R69 of VHL (54-213) was mutated to alanine, was generated using a QuickChange II site-directed mutagenesis kit (Agilent) according to the manufacturer's instructions and expressed and purified as for VCB. Both were stored in 20 mM HEPES, 150 mM sodium chloride and 1 mM tris(2-carboxyethyl) phosphine (TCEP) pH 7.5. SMARCA2 BD , SMARCA4
BD and PBRM1 BD5 were expressed in Escherichia coli BL21(DE3) as N-terminal GST-fusion proteins with a TEV protease cleavage site. Expression and purification of these proteins has been described previously 43, 44 . Starter cultures were grown overnight at 37 °C in 10 ml of Luria-Bertani medium with ampicillin (100 μg ml −1 ). The starter cultures were diluted (1:100) in Terrific Broth medium with ampicillin (100 μg ml 25 mM HEPES, 300 mM sodium chloride, 5% glycerol, 10 mM DTT, pH 7.8; in each case supplemented with cOmplete protease inhibitors (Roche). Affinity purification was performed using Glutathione Sepharose 4B (GE Healthcare) in batch mode or on-column. Cleavage of the GST-tag was performed using TEV protease for 16 h at 4 °C, either on-column, or in solution following elution of the GST-tagged BDs with lysis buffer containing 20 mM reduced l-glutathione (Sigma Aldrich). For SMARCA2 BD , before TEV protease cleavage the eluted GST-tagged BD was first dialyzed into desalting buffer (20 mM HEPES, 250 mM sodium chloride, pH 7.0, 0.5% glycerol). Where TEV cleavage was performed in solution, a second affinity (GST-trap) column purification step was carried out to remove the GST-tag and uncleaved GST-tagged protein. : 20 mM HEPES, 300 mM NaCl, 5 mM DTT, pH 7.8). All chromatography purification steps were performed either at room temperature or 4 °C using an ÄKTA FPLC purification system (GE Healthcare) or a plastic Econo-Pac column (Bio-Rad).
ITC.
Titrations for cooperativity experiments were performed at 25 °C on a MicroCal PEAQ-ITC or ITC200 micro-calorimeter (Malvern) in reverse mode (protein in syringe, ligand in cell) as described previously 7 . Briefly, PROTACs (ACBI1 or ACBI2) were diluted from a 10 mM DMSO stock solution to 20 Fluorescence polarization competition assays. To evaluate cooperativity of PROTAC binding to VCB in the absence or presence of saturating concentrations of each bromodomain, an existing fluorescence polarization assay in competition format was used, with only minor modifications 30, 34 . Fluorescence polarization experiments were performed at room temperature on a PHERAstar FS (BMG LABTECH) in 384-well plates (Corning 3820), with excitation at 485 nm and emission at 520 nm. The fluorescent peptide employed in these experiments was a 5,6-carboxyfluorescein (FAM)-labeled HIF-1α peptide (FAM-DEALAHyp-YIPMDDDFQLRSF, measured K d for VCB ~1-2 nM) ('JC9'). The assay buffer was 100 mM BIS-TRIS, 100 mM NaCl, 1 mM DTT, pH 7, supplemented with compound/DMSO vehicle (final DMSO concentration 1%). The final assay volume per well was 20 µl. A direct titration of VCB against the fluorescent peptide was first performed using 5 nM of peptide and decreasing concentrations of VCB (15-point two-fold serial dilution from 100 µM to 6.1 nM, triplicate wells). Next, a competition experiment was performed using each PROTAC (14-point half-log-fold serial dilution from 50 µM to 0.016 nM) in the absence or presence of a saturating concentration of SMARCA2 BD , SMARCA4
BD or PBRM1
BD5
(75 µM for SMARCA2 BD , 150 µM for SMARCA4 BD and 100 µM for PBRM1 BD5 ). The concentration of bromodomain was calculated such that it remained in molar excess relative to PROTAC, with the lowest concentration selected being greater than ten-fold the weakest PROTAC K d for that particular bromodomain (>90% fractional occupancy). For each independent experiment, titrations were performed using duplicate wells. IC 50 values were calculated in Prism (v.7.03, GraphPad). Curves were fitted using nonlinear regression (four-parameter fit) following normalization to percentage of maximum signal on the basis of corresponding DMSO controls for each treatment type. K i values were backcalculated from fitted IC 50 values as described previously 30, 34 . Cooperativity values (α) for each PROTAC were calculated using the ratio:
The reported values are the mean ± s.e.m. from three independent measurements (duplicate wells).
TR-FRET competition assays. To evaluate cooperativity of PROTAC binding to SMARCA2
BD , a TR-FRET assay was developed in a competition format using a biotinylated SMARCA2 probe 28 (K d for SMARCA2 BD ~400 nM) and His 6 -tagged SMARCA2 BD . PROTAC binding to SMARCA2 BD was then measured in the absence or presence of saturating concentrations of VCB.
All assays were performed at room temperature in a Proxiplate-384 PLUS, white (PerkinElmer) plate. Reagents were diluted in buffer, consisting of 50 mM HEPES, 50 mM sodium chloride, 2 mM DTT, 0.008% Brij, 0.01% BSA at pH 7.3, and were allowed to equilibrate to room temperature before addition to plates. The final concentrations in the assay were as follows: 40 nM SMARCA2 BD , a concentration series of each PROTAC (10 µM to 1 nM, 11-point half-log-fold serial dilution), 16.6 nM biotinylated probe 5, 2.5 nM Lance Eu-W1024 labeled streptavidin (PerkinElmer Cat No. AD0062, 50 µg, 500 µg ml ) and either assay buffer or 5 µM VCB at a final DMSO concentration of 1%. SMARCA2 BD , streptavidin-Eu and ULight AB were mixed in assay buffer (SMARCA2 solution) and kept at room temperature before use. Then, 5 nl of the biotinylated probe solution was added to rows 1-23 (with the Labcyte Echo 55x) and 187.5 nl VCB (or assay buffer) was transferred with the Labcyte Echo 55x to rows 1-23. Then, 15 µl of the SMARCA2 solution was added to rows 1-24. Plates were incubated at room temperature for 60 min and the signal was measured in a PerkinElmer Envision HTS Multilabel Reader using the TR-FRET LANCE Ultra specs from PerkinElmer (665 nm/615 nm × 10,000).
Each plate contained 16 wells of a negative control (diluted DMSO instead of test compound with biotinylated probe) and 16 wells of a positive control (diluted DMSO instead of test compound without biotinylated probe). The average of the background control (positive control, without enzyme) was calculated and subtracted from the measured values for each plate. IC 50 values were calculated and analyzed using a four-parametric logistic model for each PROTAC in the absence or presence of saturating concentrations of VCB. Cooperativity values (α) for each PROTAC were calculated using the ratio: 50 50 Note that 'VCB' represents either VCB or VCB
R69A
.
The reported values are the mean ± s.e.m. from three independent measurements (duplicate wells). BD were soaked for 5 days, then flash cooled in liquid nitrogen using reservoir solution containing 25% ethylene glycol as a cryo-protectant. Data were collected at the SLS beamline PXII (Swiss Light Source, Paul Scherrer Institute, λ = 1.000 Å) using a PILATUS 6 M detector. The crystals belonged to space group P 4 1 with unit cell parameters a = 42.5, b = 42.5, c = 164.2 Å and α, β, γ = 90° and contained two monomers per asymmetric unit. Images were processed with autoPROC incorporating STARANISO (http://www. globalphasing.com) 45 . The resolution limit was set to 1.33 Å using local(I/σI) ≥1.20. The structure was solved by molecular replacement using a SMARCA2 BD crystal structure (PDB entry 4QY4; https://www.thesgc.org/structures/4qy4) as a search model. Subsequent iterative model building and refinement was done according to standard protocols using CCP4 (ref. 46 ), COOT (ref. 47 ) and autoBUSTER (Global Phasing Ltd). The structure was refined to R work and R free values of 17.9 and 19.3%, respectively, with 100% of the residues in Ramachandran favored regions as validated with MOLPROBITY 48 . Ligand restraint and initial coordinate files for all structures were generated using GRADE (http://www.globalphasing.com) incorporating crystallographic geometry information from MOGUL 49 . Data collection and refinement statistics for all structures are described in Supplementary Table 1.
VCB:PROTAC 1:SMARCA2
BD ternary complex crystallography. VCB, PROTAC 1 and SMARCA2
BD were mixed in a 1:1:1 stoichiometric ratio in 20 mM HEPES, pH 7.5, 150 mM sodium chloride, 1 mM TCEP, 2% DMSO, incubated for 5 min at room temperature and concentrated to a final concentration of approximately 8 mg ml −1 . Drops were prepared by mixing 1 μl of the ternary complex with 1 μl of well solution and crystallized at 4 °C using the hanging-drop vapor diffusion method. Crystals were obtained in 18% (w/v) PEG 3350, 0.2 M sodium formate, 0.1 M HEPES, pH 7.75, and formed within 24 h but were fully grown after a few days. Harvested crystals were flash cooled in liquid nitrogen following gradual equilibration into cryo-protectant solution consisting of 25% (v/v) ethylene glycol in 19% PEG 3350, 0.2 M sodium formate, 0.1 M HEPES, pH 7.75. Diffraction data were collected at Diamond Light Source beamline I04-1 (λ = 0.91587 Å) using a Pilatus 6M-F detector and processed using XDS 50 . The crystals belonged to space group P 2 1 2 1 2 1 with unit cell parameters a = 79.7, b = 117.3, c = 121.6 Å and α, β, γ = 90° and contained two copies of the ternary complex per asymmetric unit. The structure was solved by molecular replacement using PHASER with VCB coordinates derived from the VCB:MZ1:Brd4 BD2 complex (PDB entry 5T35) and SMARCA2 BD (PDB entry 4QY4) 51 as search models. Subsequent iterative model building and refinement was done according to standard protocols using CCP4 (ref. . The crystals belonged to space group P 2 1 2 1 2 1 with unit cell parameters a = 80.5, b = 116.2, c = 120.6 Å and α, β, γ = 90° and contained two copies of the ternary complex per asymmetric unit. The structure was solved by molecular replacement and built, refined and the geometry validated as for the VCB:PROTAC ) was prepared and crystallized in well solution comprising 20% (w/v) PEG 1,500, 0.1 M MIB buffer, pH 6.0. Harvested crystals were flash cooled in liquid nitrogen following gradual equilibration into cryo-protectant solution consisting of 25% (v/v) ethylene glycol in 25% PEG 1500, 0.1 M MES, pH 6.0. Diffraction data were collected at SLS beamline X10SA (λ = 1.000 Å) using a Pilatus3 6 M detector and processed using AUTOPROC. The crystals belonged to space group P 1 with unit cell parameters a = 66.3, b = 61.7, c = 81.6 Å and α = 69.4, β = 83.4, γ = 86.4° and contained two copies of the ternary complex per asymmetric unit. The structure was solved by molecular replacement and built, refined and the geometry validated as for the VCB:PROTAC 1:SMARCA2 BD ternary complex, to final R work and R free values of 21.6 and 23.6%, respectively, with 97.4% of the residues in Ramachandran favored regions as validated with MOLPROBITY 9 .
Transfection, lysis and protein detection for AlphaLISA assays. Human embryonic kidney (HEK)293 cells in DMEM (Invitrogen) were seeded at 3-3.5 × 10 5 cells per well of six-well plates and the medium was replaced on the day of transfection. The pIRESpuro3 vector (Clontech) containing an insert for C-terminal 3× FLAG-tagged wild-type SMARCA2 (Uniprot identifier: P51531-1) or SMARCA4 (P51532-1) were transiently transfected into HEK293 cells using lipofectamine 2000 (Invitrogen) and OptiMEM (Invitrogen). Untransfected cells and cells transfected with the empty vector were used as negative controls. After 48 h, cells were washed twice in cold PBS (Invitrogen) and lyzed in hypotonic buffer containing 10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 50 units per ml benzonase nuclease (Sigma) and protease inhibitor cocktail (Roche) by Dounce homogenization. Protein samples were cleared by centrifugation at 4 °C, at 1,000g for 5 min and the supernatants stored at −80 °C. Protein concentration was determined by bicinchoninic acid (BCA) assay (Pierce) and the absorbance at 562 nm measured by spectrophotometry (NanoDrop ND1000). Samples were separated by SDS-PAGE using 40 μg of protein per well of NuPAGE Novex 4-12% BIS-TRIS gels (Invitrogen) and transferred to 0.2 μm pore nitrocellulose membrane (Amersham) by wet transfer. Overexpression was confirmed by Western blot detection of mouse anti-FLAG (1:1,000, Sigma no. F1804), rabbit anti-SMARCA2 (1:1,000, Sigma no. HPA029981), rabbit anti-SMARCA4 (1:1,000, abcam no. 49360) and rabbit anti-β-actin (1:25,000, Cell Signaling Technology, no. 4970 S) antibodies with goat anti-mouse or donkey anti-rabbit IRDye 800CW secondary antibodies (1:10,000, LI-COR no. 925-32210 and no. 926-32213, respectively) using a ChemiDoc MP imaging system (Bio-Rad). Quantification of band intensity was performed in Image Studio Lite (LI-COR) and normalized to β-actin expression and the DMSO control.
Ex cell AlphaLISA competition assays. Protein lysates containing either FLAGtagged SMARCA2 or SMARCA4, were used for evaluation of ternary complex formation with full-length protein. Three biological repeats were performed with protein from three separate transfections and assay wells were run in duplicate. All assays were performed at room temperature in 384-well alphaplates (PerkinElmer) with a final assay volume of 30 μl. Before each 1 h incubation, plates were sealed with film (PerkinElmer), centrifuged at 100g for 30 s and mixed by shaking at 450 r.p.m. for 2 min. All assay components were made up as 6× stocks in assay buffer (50 mM HEPES pH 7.5, 100 mM NaCl, 0.1% w/v BSA, 0.02% w/v CHAPS, 0.2 μm filtered). A 12-point, half-log-fold dilution series was used for all PROTACs and untagged VCB. The biotinylated SMARCA2 probe 28 (100 nM final) and excess untagged VCB (5 μM-50 μM final) or an equivalent volume of assay buffer were incubated with PROTAC (all 0.1 nM-31.62 μM final) and 15 μg protein lysate or equivalent volume of lysis buffer for 1 h. Anti-FLAG beads (10 μg ml −1 final, PerkinElmer) were added in low light conditions and incubated for 1 h in the dark. Anti-streptavidin acceptor beads (10 μg ml −1 final, PerkinElmer) were added in low light conditions and incubated for 1 h in the dark. Plates were read on a PHERAstar FS (BMG LABTECH) with an AlphaLISA optic module (BMG LABTECH, excitation 680 nm and emission 615 nm). Signal intensity was plotted against PROTAC concentration in GraphPad Prism 7. Data was normalized to the average DMSO signal intensity for binary (without VCB) and ternary (with VCB) values and the percentage signal plotted with an inhibitor versus response variable slope four-parameter fit with a bottom constraint equal to zero. The binary IC 50 was divided by the ternary IC 50 to generate the α value. SPR binding studies. SPR experiments were performed on Biacore 8 K or T200 instruments (GE Healthcare). Immobilization of target protein was carried out at 25 °C on a CM5 chip using amine coupling (EDC/NHS, GE Healthcare or XANTEC) in HBS-P+ running buffer, containing 2 mM TCEP, pH 7. 4 . Following activation of the surface with EDC/NHS (contact time 600 s, flow rate the Orbitrap Velos in collision-induced dissociation (CID) mode. The top 15 precursors were selected for MS2 over the mass range of 335-1,800 (m/z) at a resolution of 60,000. MS2 scans were acquired with a minimum charge state of 2, a normalized collision energy of 35%, an activation time of 10 ms. Data searching and analysis: The data were processed using MaxQuant 54 , v.1.5.0.25 and the Andromeda search engine with the following parameters 55 : proteins and peptides were identified using the human UniProt database (downloaded on January 7, 2018) and peptides were searched with a fixed cysteine carbamidomethyl modification and variable methionine oxidation and N-terminal acetylation modifications and matched between runs. The t-test differences between means for protein abundance of cells treated with ACBI2 or cis-ACBI2 were calculated using LFQ intensities and plotted versus log 10 P values determined by two-tailed t-test (Perseus Software v.1.6.1.3). To test for specificity of immunoprecipitations, t-test difference of immunoprecipitations versus the IgG controls were plotted versus the log P value calculated using the means of label-free quantification (LFQ) intensities. Each experiment was performed in triplicate except the ARID1A-IP at 8 h treatment time that was performed in quadruplicate.
Statistical methods.
No statistical methods were used to predetermine sample size, experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Number of replicates, mean value and error values are described in the respective figure legends and/ or methods. Error bars are show for all data points with replicates as a measure of variation within the group. All t-tests performed were two-tailed t-tests assuming equal variances.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article. For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Validation
Antibody against SMARCA4 was validated by the presence of the respective peak in capillary electrophoresis in cell lines wild type for SMARCA4 (e.g. MV-4-11, SK-CO-1), the absence of the peak in cell lines that lack SMARCA4 expression (e.g. NCI-H1568, SK-MEL-5, A549) and the reappearance of the band in cell lines engineered to express SMARCA4 from a retroviral construct. Antibody against PBRM1 was validated by the presence of a peak at the appropriate size in in capillary electrophoresis as presented by the manufacturer and by the presence of the band in immune precipitates of the BAF complex in Western blots. Antibody against SMARCA2 was validated by siRNA knockdown. Antibody against FLAG was validated by the presence of a band in transfected cells corresponding to the MW of the protein containing the FLAG tag and absence of a band in cells transfected with empty vector. All cell lines were authenticated by STR analysis.
Eukaryotic cell lines
All cell lines were tested for mycoplasma and found negative. 
